everyone. Elif. us for you Thanks, today. joining Thank Hello,
review stands start the hard XXXX overwhelming of both for has growth. work Quantitatively, transforming future an current to I'm proud reporting our to to far say been we Before success. performance the business our fiscal at period, testimony that date thus the in company's immediate and
and This numbers. and areas facilitate identification the especially States. reflected operating our we as of with the our been over forward business. will course affairs such have the HIV This of has lipodystrophy to built includes in uncontrolled last patients put the into to teams have activities team which focused in in load. that United come diagnosis a with programs value have designed impactful viral as medical patients witnessed the investing the our own now sales is together be in which organization We of the great legacy plan, year, unlock Theratechnologies We’ve consideration
enhancing new reduces wanted the for also is of the seconds. of patients. to designed administration PK from Trogarzo for expand safety methods method method to dose administration into believe only Not of improved FDA more be but clinics and experience, same profile is are providers. patient we maintenance second by new highlight administration patient we firmly that push IV XX will approval Trogarzo at to Trogarzo IV of IV recent speaking of new In healthcare increase and to patient similar easier dosing further This push We make heavily treated the formulations. time the through that minutes XX experiences adherence of the maintenance of we patients and to time. and administration Thus, able on infusion, the XX
last for Additionally, enrolled more method the a in for fully patient study next and could the now of is believe visit access We the intramuscular including is scheduled such as of patient an clinic treatment that even convenient to outside administration, IM pharmacy month. settings. Trogarzo new provide
The experiences. that the to up patient that market ramping in matter the we fact non-oral is strong can towards a fostering fact simple delighted commitment are demonstrate superior regimens. of We is quickly
presentation, of come time. data improved have AIDS push Conference better not Incidentally, treatment the So, the at a for two Theratechnologies for regimens. potential approval Trogarzo at from could announced XXXX poster IV showing the
the viable. abstract for proof-of-concept be that administration formulation a additional The as endorsement This conference. completed. could Top for first abstracts of is Trogarzo presentation the study was demonstrated a in pharmacokinetic This another be methods big second modeling Furthermore, fully administration will data experienced supporting which shortly XXX IM demonstrated by to lead could active how in combination heavily treated with agent simpler regiments selected the presentations dosing populations.
market. which now, SV on is current Moving EGRIFTA to a the formulation
the that study the well, with requested FDA instruction ongoing it human is ultimate factor treatment. The and patient to and the company announced, adherence patient to will ultimately for the fine is use. previously study carry tuning this hope that improve progressing goal out As our
As study. been to has study us we FA SV, parallel a the to This running for the do and study as for human factor one have proactively do to EGRIFTA well. formulation asked FDA near is the decided initiated has in SV
and the on in for currently this strategy, track of our We a bacteriostatic to settling quarter the Given control formulation the formulation in fourth filing to uncertainty the believe to the of regarding manufacturer we have this this static contract matters XXXX injection, and decided date XXXX. FA up situation have launch water In will firm launch. with take upon a launch new signed I this water to take timeline the our an water the forward into of with bacterial lipodystrophy we deliver ourselves. supply quarter own of first are hands of FA’s a and ensure supply continuous agreement for targeted of go source
Now, business the is in with put and as go, in in swing. full sales overview reporting and our continues quarter momentum level that a force of the to place more high period, have one we
report and periods consolidated for up Trogarzo provide achieving into more SV such, XX% are in-line to that revenue sales new fiscal growth to the performance, product performance be million date, new which patient does diagnosis date To that more heights a XX are insights numbers reporting our XX while revenues to on As revenue by on and U.S. financial year EGRIFTA objectives. we Philippe being driven include Europe. of XX%. up million, identification will confident guidance lipodystrophy deliver year. both Trogarzo. in will we to usual is happy call, on today's year with our is This between facilitate we're strategy specific as are while the XX% for patients blended
unencumbered. institutional healthcare second also financing a confidence financial million lifts investor. major Thera, the a a on non-dilutive having Not announced this to separately our and commercial pipeline of the for burden of credit us of debenture oncology only technologies in of Asset noted commercial is powerful our development future we which the Marathon our was advancement signing with the SORTX+ convertible the remain further call, Management, of execute June growth As due plans repay the And in new our the agreement with quarter turn XXXX, to platform. exciting, associated very activities vote XXX while to allows
in our patients. basket the that of were THXXXX provided or have As X we and of on disease preclinical to update of in many that work is and to recurrence. we the industry resistance demonstrate cells. ovarian stem of such, we was in In studies, inhibiting observed the causes efficacy we the THXXXX shown docetaxel triple-negative current patients treatment in quarter, by escalation laser bypass receptor pretreated and Phase to body like cancer breast drug models. human was potential publications by cells underlying evidence mimicry in failure issue contributing three technology Earlier vitro, It can which targeting resistance really noticed alone. of with in and pathways [ph]. to The cancer ovarian vivo as SORTX+ versus of of docetaxel the drug vitro recruiting in of the part publication remain highlighted [recognized and the pharmaceutics] vasculogenic getting targeting mechanisms efficacy announced focused This of adding performing prior breast inhibition peptide also our and first data on SORTX for metastatic cancer in vivo dose vitro benefits evidence special that an THXXXX conjugate the signs stem and is both preclinical further published the and in are journal therapy. THXXXX The advancing in enhanced in featured and study trial. The heavily for announced like served
with from that efficacy the recurring as cell stem include benefits [indiscernible] the cancer cells comes often excitement can fact cancers. Our therapeutic hidden potential cancer act as sustained associated
that place have been a new take joint Just end yesterday, announced showing month session conference oncology of in will expression the the types. poster a at data highly ENA, cancer to high presented The in be will that we the Spain. recognized in at symposium SORTX present receptor data several XXth selected Barcelona, of of we
an our others mechanism where gives able continue progress. to program's to succeeding it of chance been believe that not We unique exceptional have action of
partnership THXXXX moving are the as trial basket China continues. the sensing of front, discussions enrollment forward On outline and
we from Finally, the our in making field By as many per identified NASH a Recent program resources this until with rejuvenated remains as has costly are investors endeavor. of interest have responsibly partner the forward. advancing news previous vis-à-vis to the acting capabilities and communications, condition is pause on the to program, we program positive NASH this partnering investors. a carry a
in more program a forward. would the compartments, late ever a now As Officer. the phase feel than one Philippe, [ph], call in NASH the targets of mechanism and that accumulation move Chief only with dis-regulation the to action we including of this pass like seeing of partner Financial to in, fat our the companies [indiscernible] finding I optimistic [liver]
